"We are very excited to have been selected by Health Robotics as their long-term exclusive CytoCare partner in Spain and Portugal, adding the Cancer Therapy Robot in our core Iberian peninsula market to our prior i.v.STATION distribution rights. CytoCare, the world's first and only robotic system designed for the safe and sterile preparation of patient-specific hazardous IV Admixtures, represents an ideal complement to our other market-leading Pharmacy Automation products. Vall d'Hebron University Hospital has demonstrated a long trajectory of innovation, utilizing new technologies to achieve excellent peer-reviewed and published efficiency and medication safety results, with prestigious awards such as Best European Pharmacy Management, ESADE's Management Innovation, and finally the Best Health Care Ideas in 2009", stated Xavier Guix, Vice President of Marketing for Grifols' Hospital System Division.
"It is very exciting to expand our i.v.STATION relationship at such a prestigious hospital as Vall d'Hebron University Hospital, with its world-renowned cancer research programme and the well-documented scientific publications by Dr. Josep Monterde and his team of scientists and pharmacists; we feel rewarded with this new contract after 1000 Bed Bolzano General Hospital hosted an inspection team from Vall d'Hebron University Hospital in order to ascertain CytoCare's speed, flexibility, and safety in comparison with other IV Robotics companies, and demonstrating that CytoCare handled 70 percent of Chemo IV doses within a 4 hour time-window. Additionally, Grifols is the perfect fit for CytoCare in Spain and Portugal due to its well-established distribution channels, commitment to patient safety, its company stability and superior market footprint, and finally its world-class service infrastructure. In addition to the obvious success in expanding our partnership with Grifols and receiving a repeat endorsement from an existing Health Robotics' partner, I'm very pleased that this new contract symbolizes the first CytoCare installation in Spain, and the eight European Union member country to embrace CytoCare for its Oncology Therapy Compounding needs", stated Werner Rainer, Health Robotics' CEO.
Vall d'Hebron University Hospital, a major hospital complex in Catalonia and one of the largest in Spain, is comprised of four large centres - the General Area, the Maternity and Children's Area, the Traumatology and Rehabilitation Area and the Outpatient Surgery Unit (Pere Virgili Health Care Park) - which cover almost all the medical and surgical specialties. The Vall d'Hebron University Hospital, with a total of more than 1400 beds, also house various teaching centres, public health care enterprises, research centres, laboratories and other complementary facilities.
Grifols International is a Spain-based company engaged in the health care sector and is listed on Ibex-35 stock market. Grifols is involved in the research, development, manufacturing and marketing of plasma derivates, IV therapy solutions, enteral and parenteral nutrition, diagnostic systems, pharmacy automation, and medical materials and devices. Founded in 1940, Grifols currently operates in 90 countries with more than 6000 employees, 26 subsidiaries with combined gross revenues over 800 million euro, and a 3 billion euro market capitalization.
"After Health Robotics' meteoric growth recently surpassed the significant milestone of 100 worldwide I.V. Automation contracts, it dictated the need to consolidate its market gains by acquiring the assets of two strategic partner companies - MEDarchiver S.r.l. and Biomedical Technology Consulting S.r.l. - that supplied products and services to Health Robotics' customers and to the I.V. Room of the Future Project. These acquisitions enable Health Robotics to: a) re-establish an IV Room presence in Italy after having temporarily exited the market in 2008 as a result of the transfer to Loccioni - CytoCare's development partner - of most of Italy's CytoCare operations; b) yield long-term cost synergies; and c) consolidate the three companies' intellectual property, customer-facing operations, and scientific knowledge within the fields of I.V. Automation and Clinical Workflow Solutions", stated Werner Rainer, Health Robotics' CEO.
MEDarchiver has built an outstanding reputation over the past decade for excellence in developing and implementing "All-Digital" life-critical software automation solutions for health care providers with exceptional innovation, ease-of-deployment, and R.O.I. results. Amongst others, assets include Cardio Web, the world's first and only nationwide Cardiology digital medical record, certified by the National Council of Cardiologists in Italy; OMM, which will serve as the company's cornerstone to expand its Cancer Therapy presence in North America, complementing CytoCare and i.v.SOFT; and MEDtpn, which enables Health Robotics to immediately offer TPN e-Prescription to its customers, and to develop TPNstation on top of an industrial-strength TPN work flow software foundation.
In anticipation of these acquisitions, Health Robotics' instituted in May and June 2010 changes to its Executive Management Team in order to have its members become more focused in specific areas of competence. Consequently, Fabio Fioravanti, Executive VP for Operations and CTO, assumed in June all responsibilities encompassing quality assurance, product development, implementation, operations, manufacturing, and customer support; Gaspar DeViedma ceased his General Counsel duties last May to focus exclusively on sales, product marketing, and joint-development activities worldwide, including MEDarchiver solutions outside of Italy; Paolo Giribona now exclusively concentrates on research activities related to new products such as TPNstation; and finally Werner Rainer continues as CEO of Health Robotics while exclusively centering his efforts on the I.V. Room of the Future, utilizing MEDarchiver's customer base to re-enter the Italian market for I.V. Automation, and directly supervising the newly formed 10-member Health Robotics' Scientific Advisory Board, whose contributors are announced in August 2010.
Biomedical Technology Consulting has led technology assessments and work flow re-design projects in Italy, Germany, France, Luxemburg, Switzerland, Croatia, Serbia, Romania, Albania, United Arab Emirates, Qatar, Iraq, Cyprus, and Vietnam, with extensive experience in the I.V. Room, Pharmacy, Cardiology, Anaesthesiology, PACS, and Nursing segments.
Expected immediate synergies from the merged companies include a single customer help-desk; integrated R&D, quality assurance and production teams; one-stop distribution channels; and the acquisition of key personnel assets. MEDarchiver will continue to operate as a division of Health Robotics, focusing on integrated and "All-Digital" work flow automation solutions in its established local markets, while benefiting from exporting best-of-class Oncology, Cardiology and other medical error-avoidance technology solutions throughout Health Robotics' worldwide distribution network. Health Robotics will continue investing into and expanding MEDarchiver markets, and showcasing its "All-Digital" health care installations, such as Campus Biomedico University Hospital and La Maddalena Cancer Institute.
Health Robotics Canada Inc.'s impressive results included new North American contracts for 4 i.v.STATION, 4 i.v.SOFT, and 3 I.V. Room of the Future projects, bringing Health Robotics' 2010 first semester total to 26 new American contracted installations, compared to 1 new contract announced by all of the direct competitors combined within the same 6-month period, and to zero contracts signed by the prior North American distribution channels during the entire 2009 year.
"We had an outstanding second consecutive quarter of operations in the USA and Canada including the first-ever American i.v.STATION contracts at a Paediatric hospital and an Outsourcing Pharmacy; the first worldwide contract for i.v.SOFT at a Paediatric hospital; and the first i.v.Room of the Future agreement at a regional hospital network (IDN). Combined with international results, we have now reached 105 contracted installations around the world. Due to the record demand for both i.v.STATION and i.v.SOFT, HRCI will close down this Summer its Early-Adopter discount programmes for these two products, self-constraining future 3Q North American sales to five extra units (each) of i.v.STATION and i.v.SOFT Assist for installation in 4Q2010, with the remainder of future sales contracts to be scheduled for 2011 installation slots. We expect our upgraded North American sales channel partners to significantly add additional new contracted installations to the implementation backlog during 3Q2010", stated Werner Rainer, Health Robotics' CEO.
New contracts for installations of 4 i.v.STATION robots were signed by The Cleveland Clinic Foundation, Long Beach Memorial Hospital, Miller Children's Hospital, and finally Health Robotics' first I.V. Outsourcing customer: Pharmacie Linda Frayne & John DiGenova, Montréal. All of these robots are scheduled to "go-live" before the end of 2010, as Health Robotics has now achieved the ability to move to a standard and more streamlined implementation work-plan and schedule, made possible by the results and experience gathered by earlier i.v.STATION Beta Tests in Europe and the United States of America.
Additionally, Ochsner Clinic Foundation, Sutter Health-Sacramento Sierra Region, and USC University Hospital signed 3 new exclusive contracts for the I.V. Room of the Future, including their respective Chief Pharmacy Officers participation in Health Robotics' Scientific Advisory Board, where they will shortly join The Cleveland Clinic Foundation.
Finally, 4 new contracts for installations of i.v.SOFT Assist, Profile, and Label+ work flow software automation modules were executed by Children's Hospital of Los Angeles, Ochsner Clinic Foundation, University of Massachusetts Medical Center, and USC University Hospital. These new i.v.SOFT installations are to follow in 3Q2010 the already in-progress Beta-Tests installations announced last April for both Chemotherapy and for Non-Hazardous IVs, and to be completed over the next few months at Brigham & Women's Hospital, The Cleveland Clinic Foundation, Duke University Medical Center, University of Chicago Medical Center, and the University of Texas MD Anderson Cancer Center.
"Expanding our CytoCare relationship with Health Robotics to these additional products has been an strategic goal of ours for quite some time, as we believe that the cost and small footprint of these innovative products together with their applicability to all Korean acute care hospitals as opposed to only Cancer Centers gives us the ability to enhance our objective to maximize market share and to offer end-to-end IV Automation solutions to our customers in the Republic of Korea", stated Bum Kyo Lee, CEO of BioRobotics.
i.v.STATION represents a revolutionary approach in the quest for safe, accurate, efficient, cost-effective, and ready-to-administer intravenous patient doses. It offers unprecedented reduction of medication errors, ISO-compliant accuracy, improved sterility, and clinician labour savings: all within a scalable, cost-effective, distributed, and fail-safe architecture. i.v.SOFT constitutes an ideal complement to CytoCare and i.v.STATION both as a means to back-up robotic devices and to direct excess IV Admixture production demand and non-standard IV consumables - i.e. cassette pumps, ampoules, glass bottles, IV doses requiring the use of CSTDs, etc. - towards Laminar Airflow Hoods.
"It is a pleasure to renew our commitment and strategic partnership with BioRobotics and to ship the first i.v.STATION robot to Korea for installation in December 2010. We are confident that BioRobotics' technical expertise with Surgery Robots positions them to take full advantage of our new products. Additionally, this new strategic agreement marks the significant milestone for Health Robotics of completing mainland Asia marketing and service channels' coverage for i.v.STATION, with only Taiwan and Oceania channel strategies remaining to be determined over the next few months", stated Gaspar DeViedma, Health Robotics' Executive Vice President.
Founded in 1995, BioRobotics is currently a major medical robotics supplier and the second largest medical importing business in the Republic of Korea with US $27 million import volume during the year 2008. The company originally started in the Aesthetic laser surgery and Cryosurgery medical sectors and further expanded into robotic surgery in 2005. In only 4 years since the launch of Oncology Robotics in its core market, BioRobotics has already achieved twenty-four (24) installations of the daVinci Surgical robot in the Republic of Korea.
Health Robotics is a global supplier of life-critical intra-venous medication robots, providing health care facilities in 5 continents with robotics technology and software automation solutions deployed utilizing virtual high-availability technology. Its world-leading solutions CytoCare (hazardous IVs), i.v.STATION (non-hazardous IVs), i.v.SOFT (work flow engine for manual compounding), and TPNstation (totally-automated parenteral nutrition) have and will greatly contribute to ease hospitals' growing pressures to improve patient safety, increase throughput and contain costs. Through the effective and efficient production of sterile, accurate, tamper-evident and ready-to-administer IVs, Health Robotics' solutions help hospitals eliminate life-threatening drug-exchange errors, decrease other therapy oversights and sterility risks, work more efficiently, reduce waste and controlled substances' diversion, and diminish the gap between rising patient volume/acuity and scarce nursing and pharmacy staff.